HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes

Toxicology Letters

Volumn 93, Issue 2-3, 1997, Pages 215-219

  Inaba, T ^a   Fischer, N E ^a   Riddick, D S ^a   Stewart, D J ^a   Hidaka, T ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b KANEKA CORPORATION   (Japan)

Author keywords

Benzoxazinorifamycin KRM 1648; Cytochrome P450 3A4; HIV protease inhibitors; Human liver; Testosterone

Indexed keywords

CYTOCHROME P450; INDINAVIR; PROTEINASE INHIBITOR; RIFALAZIL; RITONAVIR; SAQUINAVIR; TESTOSTERONE;

ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ANTIBIOTICS, ANTITUBERCULAR; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RIFAMYCINS; RITONAVIR; SAQUINAVIR; TESTOSTERONE;

EID: 0031455260     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(97)00098-2     Document Type: Article

References (15)

1. Barry M., Gibbons S., Back D., Mulcahy F. Protease inhibitors in patients with HIV disease. Clin. Pharmacokinet. 32:1997;194-209.
2. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258.
3. Blaschke T.F., Skinner M.H. The clinical pharmacokinetics of rifabutin. Clin. Infect. Dis. 22:1996;5-22.
4. Chiba M., Hensleigh M., Nishime J.A., Balani S.K., Lin J.H. Role of cytochrome P450 3A4 in human metabolism of MK-639 (indinavir), a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1996;307-314.
5. Chiba M., Hensleigh M., Lin J.H. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem. Pharmacol. 53:1997;1187-1195.
6. Collier A.C., Coombs R.W., Schoenfeld D.A. et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. AIDS clinical trials group. New Engl. J. Med. 334:1996;1011-1017.
7. Eagling V.A., Back D.J., Barry M.G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:1997;190-194.
8. Fitzsimmons M.E., Collins J.M. Selective biotransformation of the human immuno-deficiency virus protease inhibitor saquinavir by small-intestinal cytochrome P450 3A4. Potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25:1997;256-266.
9. Fujii K., Tsuji A., Miyazaki S., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob. Agents Chemother. 38:1994;1118-1122.
10. Jurima-Romet M., Crawford K., Cyr T., Inaba T. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and antifungals. Drug Metab. Dispos. 22:1994;849-857.
11. Kumar G.N., Rodrigues D.A., Buko A.M., Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor Ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;423-431.
12. Mae T., Hosoe K., Fujii K., Yamashita K., Yamane T., Hidaka T., Ohashi T. In vitro metabolism of a rifamycin derivative (KRM-1648) by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotica. 26:1996;793-802.
13. Shimada T., Yamazaki M., Mimura M., Inui Y., Guengerich F.P. Inter-individual variations in human liver cytochrome P450 enzymes: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-421.
14. Waxman D.J. P450-catalyzed steroid hydroxylation: assay and product identification by thin-layer chromatography. Methods Enzymol. 206:1991;249-267.
15. Wrighton S.A., Vandenbraden M., Stevens J.C., Shipley L.A., Ring B.J., Rettie A.E., Cashman J.R. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25:1993;254-284.